Newark, United States
CorriXR Therapeutics, founded in 2022, is an emerging force in the biotechnology and health care sectors. Based in the United States, the company is carving out a niche in the development of oncology-focused biotherapeutics through its revolutionary in vivo gene editing platform.
The company is utilizing CRISPR/Cas technology with the ambition of addressing drug-resistant solid tumors, positioning itself on the cutting edge of genetic medicine innovation. Over its initial stages, CorriXR Therapeutics has transitioned from an ambitious vision to a tangible venture in the pre-clinical phase of gene editing therapeutics.
Garnering attention in the investment community, CorriXR Therapeutics recently secured a Seed Round investment on January 16, 2024, backed by Cortado Ventures. This investment signals confidence in the company's promise as a transformative biotherapeutics player. As CorriXR Therapeutics progresses, it holds potential as a high-impact investment in oncology and biotech therapeutics development.
